PriceTargets.com logo

NGM Biopharmaceuticals - NGM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 152.98%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.36 As of 06/5/2023 01:47 PM ET
▲ +0.11 (3.38%)

This chart shows the closing price for NGM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NGM Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGM

Analyst Price Target is $8.50
▲ +152.98% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $8.50, with a high forecast of $25.00 and a low forecast of $4.00. The average price target represents a 152.98% upside from the last price of $3.36.

This chart shows the closing price for NGM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in NGM Biopharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2023CitigroupInitiated CoverageBuy$6.00Low
3/30/2023B. RileyLower TargetBuy$8.00 ➝ $7.00Low
10/20/2022Piper SandlerLower Target$4.00Low
10/18/2022CowenLower TargetOutperform$32.00 ➝ $9.00Low
10/18/2022CowenLower TargetOutperform$32.00 ➝ $9.00Low
10/17/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$42.00 ➝ $4.00Low
10/17/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$29.00 ➝ $4.00Low
10/17/2022B. RileyLower Target$29.00 ➝ $8.00Low
10/17/2022Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
10/17/2022Piper SandlerDowngradeOverweight ➝ NeutralN/A
10/7/2022B. RileyLower TargetBuy$35.00 ➝ $29.00Low
7/20/2022Jefferies Financial GroupInitiated CoverageBuy$25.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$34.00 ➝ $29.00Low
3/2/2022Raymond JamesDowngradeStrong-Buy ➝ OutperformHigh
1/7/2022Piper SandlerBoost Target$30.00 ➝ $32.00High
11/5/2021Raymond JamesBoost TargetStrong-Buy$39.00 ➝ $42.00Medium
9/16/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$29.00 ➝ $35.00High
9/13/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$27.00 ➝ $39.00High
9/7/2021B. RileyBoost TargetBuy$32.00 ➝ $35.00High
8/9/2021CowenBoost TargetOutperform$20.00 ➝ $32.00Low
8/9/2021BMO Capital MarketsBoost TargetOutperform$20.00 ➝ $29.00Low
8/6/2021Raymond JamesBoost TargetOutperform$22.00 ➝ $27.00Medium
8/6/2021Piper SandlerBoost TargetPositive ➝ Overweight$20.00 ➝ $30.00High
5/24/2021Stifel NicolausLower TargetBuy$43.00 ➝ $22.00Medium
5/24/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$52.00 ➝ $22.00N/A
3/5/2021Raymond JamesBoost TargetStrong-Buy$50.00 ➝ $52.00High
3/5/2021Chardan CapitalBoost TargetBuy$39.00 ➝ $44.00High
2/9/2021The Goldman Sachs GroupBoost TargetBuy$28.00 ➝ $38.00Low
1/8/2021Raymond JamesBoost TargetStrong-Buy$32.00 ➝ $50.00Low
1/5/2021Stifel NicolausReiterated RatingTop PickN/A
12/21/2020Smith Barney CitigroupBoost Target$28.00 ➝ $44.00Medium
12/14/2020B. RileyBoost TargetBuy$30.00 ➝ $38.00Medium
10/20/2020Chardan CapitalReiterated RatingBuy$39.00High
8/14/2020B. RileyReiterated RatingBuy$30.00High
8/13/2020Chardan CapitalLower TargetBuy$40.00 ➝ $39.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$30.00High
7/7/2020Chardan CapitalInitiated CoverageBuy$40.00High
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$30.00High
5/21/2020B. RileyReiterated RatingBuy$30.00Low
5/18/2020Stifel NicolausReiterated RatingBuy$32.00Medium
5/14/2020Raymond JamesBoost TargetStrong-Buy$31.00 ➝ $32.00Medium
4/19/2020Raymond JamesInitiated CoverageStrong-Buy$31.00Low
4/6/2020Raymond JamesInitiated CoverageStrong-Buy$31.00High
3/27/2020CitigroupLower TargetBuy$34.00 ➝ $28.00High
3/23/2020CowenReiterated RatingBuy$30.00Low
3/19/2020Stifel NicolausLower TargetBuy$33.00 ➝ $32.00High
3/19/2020B. RileyReiterated RatingBuy$30.00High
2/26/2020B. RileyBoost Target$24.00 ➝ $30.00Low
2/25/2020Stifel NicolausBoost TargetBuy$26.00 ➝ $33.00High
2/25/2020CitigroupBoost TargetPositive ➝ Buy$31.00 ➝ $34.00High
2/24/2020B. RileyReiterated RatingBuy$24.00 ➝ $24.00High
2/24/2020CowenReiterated RatingBuyHigh
2/11/2020B. RileyReiterated RatingBuy$24.00Medium
12/10/2019CitigroupReiterated RatingBuy$31.00Medium
12/4/2019Stifel NicolausReiterated RatingBuy$26.00High
10/17/2019B. RileyInitiated CoverageBuy$24.00High
8/14/2019Stifel NicolausReiterated RatingBuy$26.00Low
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$26.00High
5/20/2019CowenReiterated RatingBuy$25.00Medium
4/29/2019CitigroupInitiated CoverageBuy ➝ Buy$29.00High
4/29/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$22.00Medium
4/29/2019CowenInitiated CoverageOutperform ➝ Outperform$25.00Medium
(Data available from 6/5/2018 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
11/7/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

NGM Biopharmaceuticals logo
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $3.36
Low: $3.24
High: $3.41

50 Day Range

MA: $3.74
Low: $2.98
High: $4.53

52 Week Range

Now: $3.36
Low: $2.84
High: $18.25

Volume

55,518 shs

Average Volume

310,296 shs

Market Capitalization

$276.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of NGM Biopharmaceuticals?

The following Wall Street research analysts have issued stock ratings on NGM Biopharmaceuticals in the last twelve months: B. Riley, Citigroup Inc., Cowen Inc, Cowen Inc., Jefferies Financial Group Inc., Piper Sandler, Raymond James, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for NGM.

What is the current price target for NGM Biopharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for NGM Biopharmaceuticals in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 161.5%. Jefferies Financial Group Inc. has the highest price target set, predicting NGM will reach $25.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.00 for NGM Biopharmaceuticals in the next year.
View the latest price targets for NGM.

What is the current consensus analyst rating for NGM Biopharmaceuticals?

NGM Biopharmaceuticals currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NGM will outperform the market and that investors should add to their positions of NGM Biopharmaceuticals.
View the latest ratings for NGM.

What other companies compete with NGM Biopharmaceuticals?

Other companies that are similar to NGM Biopharmaceuticals include I-Mab, Acrivon Therapeutics, PMV Pharmaceuticals, Prelude Therapeutics and Reneo Pharmaceuticals. Learn More about companies similar to NGM Biopharmaceuticals.

How do I contact NGM Biopharmaceuticals' investor relations team?

NGM Biopharmaceuticals' physical mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 243-5555 and its investor relations email address is ir@ngmbio.com. The official website for NGM Biopharmaceuticals is www.ngmbio.com. Learn More about contacing NGM Biopharmaceuticals investor relations.